ADMA Biologics (NASDAQ:ADMA) Upgraded at Wall Street Zen

ADMA Biologics (NASDAQ:ADMA) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $28.50.

ADMA Biologics Stock Up 2.6%

Shares of NASDAQ:ADMA opened at $15.57 on Friday. The business’s 50 day moving average is $17.26 and its 200 day moving average is $16.81. ADMA Biologics has a 12-month low of $13.50 and a 12-month high of $25.67. The stock has a market cap of $3.71 billion, a price-to-earnings ratio of 25.95 and a beta of 0.49. The company has a quick ratio of 3.65, a current ratio of 7.13 and a debt-to-equity ratio of 0.18.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a net margin of 28.80% and a return on equity of 39.31%. The business had revenue of $139.16 million during the quarter, compared to the consensus estimate of $139.80 million. During the same period in the prior year, the firm posted $0.46 EPS. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, sell-side analysts forecast that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

Hedge funds have recently made changes to their positions in the business. Westfield Capital Management Co. LP purchased a new stake in ADMA Biologics in the third quarter worth $74,866,000. Janus Henderson Group PLC raised its holdings in ADMA Biologics by 3,906.1% in the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after purchasing an additional 3,838,158 shares in the last quarter. Capital Research Global Investors lifted its position in shares of ADMA Biologics by 104.0% in the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after purchasing an additional 3,383,559 shares during the period. Caligan Partners LP bought a new stake in shares of ADMA Biologics during the 3rd quarter valued at about $38,653,000. Finally, UBS Group AG boosted its stake in shares of ADMA Biologics by 129.9% during the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after purchasing an additional 2,581,670 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.